Gilead Sciences, Inc.
GILDCompany Overview
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Shariah Compliance Benchmarks:
- Business Compliance: Non-Shariah compliant revenue must be less than 5% of total revenue
- Liabilities Compliance: Interest-bearing debt must be less than 33% of market capitalization
This stock meets all Shariah compliance criteria according to AAOIFI standards.
| Name | Gilead Sciences, Inc. |
| Ticker | GILD |
| Main Business | delivering innovative medicines to address unmet medical needs in virology, oncology and other therapeutic areas. |
| Type | Common Stock |
| Industry | Drug Manufacturers—General |
| Country | US |
| Market Cap | $101.26 B |
Shariah Analysis Breakdown
| Revenue Segment | Value ($M) | Non-Compliant ($M) | Reason |
|---|---|---|---|
| Product sales | $26,982.0 | $0.0 | - |
| Royalty, contract and other revenues | $299.0 | $0.0 | - |
| Total | $27,281.0 | $0.0 | 0.00% (passed) |
| Liability Item | Value ($M) | % of Market Cap |
|---|---|---|
| current debt and capital lease obligation | $1,800,000,000.0 | 1.78% |
| long term debt and capital lease obligation | $23,190,000,000.0 | 22.90% |
| Total Interest-Bearing Debt | $24,990,000,000.0 | 24.68% |
| Market Capitalization | $101,262,500,000.0 | 100.00% |
| Compliance Status | Threshold: 33% | passed |